

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Multiple Technology Appraisal (MTA)**

**Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222)**

**Matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (gemcitabine, paclitaxel and topotecan)</li> <li>• Actavis UK (gemcitabine, paclitaxel and topotecan)</li> <li>• Bristol-Myers-Squibb (paclitaxel)</li> <li>• Eli Lilly (gemcitabine)</li> <li>• Fresenius Kabi Oncology (gemcitabine, paclitaxel and topotecan)</li> <li>• GlaxoSmithKline (topotecan)</li> <li>• Hospira UK (paclitaxel)</li> <li>• Jansen-Cilag (pegylated liposomal doxorubicin hydrochloride)</li> <li>• Medac UK (gemcitabine, paclitaxel and topotecan)</li> <li>• Mylan UK (gemcitabine and topotecan)</li> <li>• PharmaMar (trabectedin)</li> <li>• Sandoz (gemcitabine and paclitaxel)</li> <li>• Sun Pharmaceuticals (gemcitabine)</li> <li>• Teva UK (gemcitabine, paclitaxel and topotecan)</li> <li>• Wockhardt (gemcitabine and paclitaxel)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Cancer 52</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Counsel and Care</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Health Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (carboplatin, cisplatin, gemcitabine, paclitaxel and topotecan)</li> <li>• Actavis UK (gemcitabine, paclitaxel and topotecan)</li> <li>• Bristol-Myers-Squibb (carboplatin, cisplatin, etoposide and paclitaxel)</li> <li>• Eli Lilly (gemcitabine)</li> <li>• Fresenius Kabi Oncology (carboplatin, gemcitabine, paclitaxel and topotecan)</li> </ul>

National Institute for Health and Clinical Excellence

Matrix for topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Equalities National Council</li> <li>• Gynae C</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Ovacome</li> <li>• Ovarian Cancer Action</li> <li>• Rarer Cancer Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Target Ovarian Cancer</li> <li>• Tenovus</li> <li>• Wellbeing of Women</li> <li>• Women's Health Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Gynaecological Cancer Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society of Urogynaecology</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• National Forum of Gynaecological Oncology Nurses</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Obstetricians &amp; Gynaecologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> </ul>	<ul style="list-style-type: none"> <li>• GlaxoSmithKline (topotecan)</li> <li>• Hospira UK (carboplatin, cisplatin and paclitaxel)</li> <li>• Jansen-Cilag (pegylated liposomal doxorubicin hydrochloride)</li> <li>• Medac UK (etoposide, gemcitabine, paclitaxel and topotecan)</li> <li>• Merck Sharp &amp; Dohme (vintafolide)</li> <li>• Mylan UK (gemcitabine and topotecan)</li> <li>• Pfizer (cisplatin)</li> <li>• PharmaMar (trabectedin)</li> <li>• Roche (bevacizumab)</li> <li>• Sandoz (carboplatin, cisplatin, gemcitabine and paclitaxel)</li> <li>• Sun Pharmaceuticals (carboplatin and gemcitabine)</li> <li>• Teva UK (carboplatin, cisplatin, etoposide, gemcitabine, paclitaxel and topotecan)</li> <li>• Wockhardt (carboplatin, cisplatin, gemcitabine and paclitaxel)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Eve appeal</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• BMJ-TAG</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul>

National Institute for Health and Clinical Excellence

Matrix for topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Society and College of Radiographers</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Black Country PCT Cluster</li> <li>• Department of Health</li> <li>• Staffordshire PCT Cluster</li> <li>• Welsh Government</li> </ul>	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

National Institute for Health and Clinical Excellence

Matrix for topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222)

Issue date: November 2012

Page 3 of 4

### **MTA Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.

National Institute for Health and Clinical Excellence

Matrix for topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222)

Issue date: November 2012

Page 4 of 4